Login to Your Account



Adolor Getting $50M Up Front In Potential $270M Glaxo Deal

By Karen Young


Tuesday, April 16, 2002
Adolor Corp. and GlaxoSmithKline plc entered a worldwide agreement to commercialize Adolor’s alvimopan in a deal with an up-front payment of $50 million to Adolor followed by the potential of $220 million more in milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription